0000000000142449

AUTHOR

Charalambos Vlachopoulos

showing 6 related works from this author

2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (…

2017

2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) : Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries

medicine.medical_specialtyCarotid artery diseasebusiness.industryAtherosclerotic diseaseUpper extremity artery diseaseGuideline030204 cardiovascular system & hematologyVascular surgeryLower extremity artery diseaseMultisite artery diseasePeripheral Arterial Diseases3. Good health03 medical and health sciences0302 clinical medicineRenal artery diseaseInternal medicinePeripheral arterial diseasemedicineCardiologyMesenteric artery disease030212 general & internal medicineVertebral artery diseaseCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

Follow-up of patients after revascularisation for peripheral arterial diseases: a consensus document from the European Society of Cardiology Working …

2019

International audience; Peripheral arterial diseases comprise different clinical presentations, from cerebrovascular disease down to lower extremity artery disease, from subclinical to disabling symptoms and events. According to clinical presentation, the patient's general condition, anatomical location and extension of lesions, revascularisation may be needed in addition to best medical treatment. The 2017 European Society of Cardiology guidelines in collaboration with the European Society for Vascular Surgery have addressed the indications for revascularisation. While most cases are amenable to either endovascular or surgical revascularisation, maintaining long-term patency is often chall…

Epidemiologymedicine.medical_treatmentDiseaseFibromuscular dysplasia030204 cardiovascular system & hematology0302 clinical medicinefollow-up030212 general & internal medicineSocieties Medicalmedicine.diagnostic_test3. Good healthEuropeNatural historyTreatment OutcomeIN-STENT RESTENOSISCardiology030211 gastroenterology & hepatologyCardiology and Cardiovascular MedicineVascular Surgical Proceduresmedicine.medical_specialtyConsensusRevascularisationFIBROMUSCULAR DYSPLASIAINFRAINGUINAL VEIN BYPASSPhysical examinationRevascularizationSTENOSISrestenosis03 medical and health sciencesperipheral arterial diseaseInternal medicinemedicineHumansVELOCITY CRITERIAbusiness.industryNATURAL-HISTORYPerioperativeVascular surgery3126 Surgery anesthesiology intensive care radiologymedicine.diseaseStenosisDUPLEX ULTRASOUND SURVEILLANCEENDOVASCULAR TREATMENT3121 General medicine internal medicine and other clinical medicineRISK-FACTORSSurgery[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCAROTID-ARTERYbusiness030217 neurology & neurosurgeryFollow-Up StudiesEuropean Journal of Preventive Cardiology
researchProduct

EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study

2021

Abstract Aims To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement. Methods and results An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis…

medicine.medical_specialtyRegistryStatinEpidemiologymedicine.drug_class030204 cardiovascular system & hematologyGuidelinesSecondary care03 medical and health sciences0302 clinical medicineEzetimibeRisk FactorsInternal medicinemedicineHumans030212 general & internal medicinePCSK9 InhibitorsDyslipidemiasSecondary preventionPrimary Health Carebusiness.industryAnticholesteremic AgentsStatinsCholesterol LDLGuidelineLipidsConfidence intervalCross-Sectional StudiesTreatment OutcomeCholesterolCardiovascular DiseasesObservational studyHydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugDA VINCI study
researchProduct

Methodology and technology for peripheral and central blood pressure and blood pressure variability measurement: current status and future directions…

2016

Office blood pressure measurement has been the basis for hypertension evaluation for almost a century. However, the evaluation of blood pressure out of the office using ambulatory or self-home monitoring is now strongly recommended for the accurate diagnosis in many, if not all, cases with suspected hypertension. Moreover, there is evidence that the variability of blood pressure might offer prognostic information that is independent of the average blood pressure level. Recently, advancement in technology has provided noninvasive evaluation of central (aortic) blood pressure, which might have attributes that are additive to the conventional brachial blood pressure measurement. This position …

Position statementmedicine.medical_specialtyAmbulatory blood pressurePhysiologycentral blood pressureBlood Pressureclinic blood pressure030204 cardiovascular system & hematologylaw.inventionperipheral blood pressure03 medical and health sciences0302 clinical medicineCentral blood pressurelawaortic blood pressuremedicineInternal MedicineHumansBlood pressure monitoring030212 general & internal medicineIntensive care medicineambulatory blood pressureSocieties Medicalbrachial blood pressurebusiness.industryself-measurementMedicine (all)Blood Pressure DeterminationPeripheralEuropemonitoringPressure measurementBlood pressurePractice Guidelines as TopicAmbulatoryblood pressure variabilitymeasurementbusinessCardiology and Cardiovascular Medicine
researchProduct

Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

2021

Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. Much of these diseases burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines are based on the sound premise that with respect to low density lipoprotein cholesterol (LDL-C), “lower is better for longer”, and the recent data have strongly emphasized the need of also “the earlier the better”. In addition to statins, which have been available for several decades, the availability of ezetimibe and inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) are additional very effective approa…

0301 basic medicineRMmedicine.medical_specialtyCombination therapyPCSK9 inhibitoreffectivenessTreatment goalsLipid-lowering therapy03 medical and health sciences0302 clinical medicineEzetimibemedicineHumansAcute Coronary SyndromeCombination therapyIntensive care medicinePharmacologyStatins.business.industryAtherosclerotic cardiovascular diseaseAnticholesteremic AgentsPCSK9StatinsEffectiveneDisease ManagementAtherosclerosisEzetimibeLipids030104 developmental biologyPCSK9 inhibitors030220 oncology & carcinogenesisPosition paperSafetybusinessVery high riskmedicine.drug
researchProduct

Editor's Choice – Follow-up of Patients After Revascularisation for Peripheral Arterial Diseases: A Consensus Document From the European Society of C…

2019

International audience; Peripheral arterial diseases comprise different clinical presentations, from cerebrovascular disease down to lower extremity artery disease, from subclinical to disabling symptoms and events. According to clinical presentation, the patient's general condition, anatomical location and extension of lesions, revascularisation may be needed in addition to best medical treatment. The 2017 European Society of Cardiology guidelines in collaboration with the European Society for Vascular Surgery have addressed the indications for revascularisation. While most cases are amenable to either endovascular or surgical revascularisation, maintaining long-term patency is often chall…

Disease030204 cardiovascular system & hematology030230 surgeryPostoperative Complications0302 clinical medicineRestenosisRecurrenceSecondary Preventionfollow-upRandomized Controlled Trials as TopicUltrasonography Doppler Duplexmedicine.diagnostic_test3. Good healthEuropeSystematic reviewPractice Guidelines as TopicIN-STENT RESTENOSISCardiologyCardiology and Cardiovascular MedicineVascular Surgical ProceduresReoperationmedicine.medical_specialtyConsensusRevascularisationINFRAINGUINAL VEIN BYPASSMEDLINEPhysical examinationSTENOSIS03 medical and health sciencesrestenosisperipheral arterial diseaseInternal medicinemedicineHumansANGIOPLASTYVELOCITY CRITERIAbusiness.industryMagnetic resonance imagingNATURAL-HISTORYPerioperativeVascular surgery3126 Surgery anesthesiology intensive care radiologymedicine.diseaseDUPLEX ULTRASOUND SURVEILLANCEENDOVASCULAR TREATMENTRISK-FACTORSSurgery[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCAROTID-ARTERYbusiness
researchProduct